Dupixent also improved lung function. Forced expiratory volume in 1 second (FEV1) is a measurement used in patients with respiratory diseases to predict the response to bronchodilator treatment and is part of the diagnosis of COPD and asthma. ...
Regeneron and SanofiwonFDA approval for Dupixent in COPD in late September 2024. The approval of the antibody in a seventh indication marked the first time the regulator had authorized a biologic in COPD. The FDA approved Dupixent on the strength of clinical data showing the drug reduces exacerba...
with other medicines for the maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and a high number of blood eosinophils (a type of white blood cell that may contribute to your COPD). DUPIXENT is used to reduce the number of flare-...
asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), eosinophilic esophagitis (EoE), prurigo nodularis, chronic spontaneous urticaria (CSU) and chronic obstructive pulmonary disease (COPD) in different age populations. More than 1,000,000...
“In this landmark phase 3 trial, patients with uncontrolled COPD achieved clinical outcomes with [dupilumab] at a magnitude never before seen with a biologic,” he said. “These results also validate the role type 2 inflammation plays in driving COPD in these patients, advancing the scientific...
Published on:September 27, 2024 Tim Smith This approval by the FDA follows positive findings from the pivotal BOREAS and NOTUS trials on adults with uncontrolled COPD. Advertisement Advertisement
Join the community. Try Seeking Alpha for free by creating an account »Create Free AccountSeeking Alpha - Power to Investors Power to Investors Follow us Download app Account Account Login Manage My Portfolio Privacy Create Portfolio Portfolio Health Check Alert Preferences Subsc...
, clinical trial sanofi and regeneron have announced results from the second investigational phase 3 notus trial for dupixent as a treatment for chronic obstructive pulmonary disease (copd), demonstrating that the drug reduced exacerbations by 34% and confirming results from the phase 3 boreas trial...